FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Wednesday

 

Cladribine Tablets Are Only a Step Away from European Union Approval for Relapsing MS





























Merck’s cladribine tablets are now just one step away from obtaining European Union approval as a relapsing MS treatment.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that the European Commission approve the tablets.

“The positive opinion from the CHMP [the committee] is an extraordinary development for our company, affirming our belief in cladribine tablets as a potential important treatment option for patients living with multiple sclerosis,” Belén Garijo, a Merck board member, said in a press release.

“We now eagerly await the European Commission decision, and the opportunity to make a difference in the MS treatment paradigm,” he said. “Our sincerest thanks to the entire MS community for their unwavering support throughout the cladribine tablets journey.”

Cladribine, whose proposed trade name is Mavenclad, is still going through clinical trials in the United States and Canada, so approval there is some time off.

Merck’s application to market cladribine in the EU was based on results of clinical trials that included about 2,700 patients and that followed some patients more than 10 years. The European Commission is expected to make a final decision on the application within 67 days of receiving the European Medicine Agency recommendation.

Information from three Phase 3 clinical trials, a Phase 2 trial and a long-term follow-up study have shown cladribine tablets to be safe and effective against relapse-remitting MS (RRMS).

The Phase 3 trials are CLARITY (NCT00213135), CLARITY EXTENSION (NCT00641537), and ORACLE-MS (NCT00725985). The Phase 2 trial is ONWARD study (NCT00436826), and the ongoing long-term study PREMIERE (NCT01013350).

Collectively, the trials have yielded information about cladribine dose levels, monitoring requirements, and side effects.

In the CLARITY trial, cladribine reduced the annual relapse rate of RRMS patients by 67 percent. Another key finding was that cladribine significantly reduced the risk of a patient’s disability worsening after six months, compared with a placebo. The risk was 82 percent lower among cladribine patients than placebo patients.

The CLARITY EXTENSION trial demonstrated cladribine’s long-term ability to control the disease. Patients received up to 20 days of treatment over two years. No additional treatments were required in years 3 and 4.

“We strongly believe in the therapeutic value of cladribine tablets and the significant impact this investigational therapy may have on the future of MS care,” said Luciano Rossetti, the head of Merck’s biopharma business research and development arm.

“There are still significant unmet needs for patients with MS, particularly those with high disease activity,” he said. “We look forward to our continued partnership with the EMA (European Medicines Agency), which has been an invaluable scientific advisor in helping us advance the development of cladribine tablets.”

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length


Go to Newer News Go to Older News